ID   AKT2_RAT                Reviewed;         481 AA.
AC   P47197;
DT   01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1996, sequence version 1.
DT   02-OCT-2024, entry version 181.
DE   RecName: Full=RAC-beta serine/threonine-protein kinase;
DE            EC=2.7.11.1;
DE   AltName: Full=Protein kinase Akt-2;
DE   AltName: Full=Protein kinase B beta;
DE            Short=PKB beta {ECO:0000303|PubMed:9512493};
DE   AltName: Full=RAC-PK-beta;
GN   Name=Akt2 {ECO:0000312|RGD:2082};
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Testis;
RX   PubMed=7999118; DOI=10.1006/bbrc.1994.2738;
RA   Konishi H., Shinomura T., Kuroda S.I., Ono Y., Kikkawa U.;
RT   "Molecular cloning of rat RAC protein kinase alpha and beta and their
RT   association with protein kinase C zeta.";
RL   Biochem. Biophys. Res. Commun. 205:817-825(1994).
RN   [2]
RP   CATALYTIC ACTIVITY, ACTIVITY REGULATION, PHOSPHORYLATION AT THR-309 BY
RP   PDPK1, AND TISSUE SPECIFICITY.
RX   PubMed=9512493; DOI=10.1042/bj3310299;
RA   Walker K.S., Deak M., Paterson A., Hudson K., Cohen P., Alessi D.R.;
RT   "Activation of protein kinase B beta and gamma isoforms by insulin in vivo
RT   and by 3-phosphoinositide-dependent protein kinase-1 in vitro: comparison
RT   with protein kinase B alpha.";
RL   Biochem. J. 331:299-308(1998).
RN   [3]
RP   REVIEW ON FUNCTION.
RX   PubMed=21620960; DOI=10.1016/j.cellsig.2011.05.004;
RA   Hers I., Vincent E.E., Tavare J.M.;
RT   "Akt signalling in health and disease.";
RL   Cell. Signal. 23:1515-1527(2011).
RN   [4]
RP   REVIEW ON FUNCTION.
RX   PubMed=21432781; DOI=10.14670/hh-26.651;
RA   Heron-Milhavet L., Khouya N., Fernandez A., Lamb N.J.;
RT   "Akt1 and Akt2: differentiating the aktion.";
RL   Histol. Histopathol. 26:651-662(2011).
RN   [5]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-451 AND SER-461, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
CC   -!- FUNCTION: Serine/threonine kinase closely related to AKT1 and AKT3. All
CC       3 enzymes, AKT1, AKT2 and AKT3, are collectively known as AKT kinase.
CC       AKT regulates many processes including metabolism, proliferation, cell
CC       survival, growth and angiogenesis, through the phosphorylation of a
CC       range of downstream substrates. Over 100 substrates have been reported
CC       so far, although for most of them, the precise AKT kinase catalyzing
CC       the reaction was not specified. AKT regulates glucose uptake by
CC       mediating insulin-induced translocation of the SLC2A4/GLUT4 glucose
CC       transporter to the cell surface. Phosphorylation of PTPN1 at 'Ser-50'
CC       negatively modulates its phosphatase activity preventing
CC       dephosphorylation of the insulin receptor and the attenuation of
CC       insulin signaling. Phosphorylation of TBC1D4 triggers the binding of
CC       this effector to inhibitory 14-3-3 proteins, which is required for
CC       insulin-stimulated glucose transport. AKT also regulates the storage of
CC       glucose in the form of glycogen by phosphorylating GSK3A at 'Ser-21'
CC       and GSK3B at 'Ser-9', resulting in inhibition of its kinase activity.
CC       Phosphorylation of GSK3 isoforms by AKT is also thought to be one
CC       mechanism by which cell proliferation is driven. AKT regulates also
CC       cell survival via the phosphorylation of MAP3K5 (apoptosis signal-
CC       related kinase). Phosphorylation of 'Ser-83' decreases MAP3K5 kinase
CC       activity stimulated by oxidative stress and thereby prevents apoptosis.
CC       AKT mediates insulin-stimulated protein synthesis by phosphorylating
CC       TSC2 at 'Ser-939' and 'Thr-1462', thereby activating mTORC1 signaling
CC       and leading to both phosphorylation of 4E-BP1 and in activation of
CC       RPS6KB1. AKT is involved in the phosphorylation of members of the FOXO
CC       factors (Forkhead family of transcription factors), leading to binding
CC       of 14-3-3 proteins and cytoplasmic localization. In particular, FOXO1
CC       is phosphorylated at 'Thr-24', 'Ser-256' and 'Ser-319'. FOXO3 and FOXO4
CC       are phosphorylated on equivalent sites. AKT has an important role in
CC       the regulation of NF-kappa-B-dependent gene transcription and
CC       positively regulates the activity of CREB1 (cyclic AMP (cAMP)-response
CC       element binding protein). The phosphorylation of CREB1 induces the
CC       binding of accessory proteins that are necessary for the transcription
CC       of pro-survival genes such as BCL2 and MCL1. AKT phosphorylates 'Ser-
CC       454' on ATP citrate lyase (ACLY), thereby potentially regulating ACLY
CC       activity and fatty acid synthesis. Activates the 3B isoform of cyclic
CC       nucleotide phosphodiesterase (PDE3B) via phosphorylation of 'Ser-273',
CC       resulting in reduced cyclic AMP levels and inhibition of lipolysis.
CC       Phosphorylates PIKFYVE on 'Ser-318', which results in increased PI(3)P-
CC       5 activity. The Rho GTPase-activating protein DLC1 is another substrate
CC       and its phosphorylation is implicated in the regulation cell
CC       proliferation and cell growth. AKT plays a role as key modulator of the
CC       AKT-mTOR signaling pathway controlling the tempo of the process of
CC       newborn neurons integration during adult neurogenesis, including
CC       correct neuron positioning, dendritic development and synapse
CC       formation. Signals downstream of phosphatidylinositol 3-kinase (PI(3)K)
CC       to mediate the effects of various growth factors such as platelet-
CC       derived growth factor (PDGF), epidermal growth factor (EGF), insulin
CC       and insulin-like growth factor I (IGF-I). AKT mediates the
CC       antiapoptotic effects of IGF-I. Essential for the SPATA13-mediated
CC       regulation of cell migration and adhesion assembly and disassembly. May
CC       be involved in the regulation of the placental development
CC       (PubMed:21432781, PubMed:21620960). In response to lysophosphatidic
CC       acid stimulation, inhibits the ciliogenesis cascade. In this context,
CC       phosphorylates WDR44, hence stabilizing its interaction with Rab11 and
CC       preventing the formation of the ciliogenic Rab11-FIP3-RAB3IP complex.
CC       Also phosphorylates RAB3IP/Rabin8, thus may affect RAB3IP guanine
CC       nucleotide exchange factor (GEF) activity toward Rab8, which is
CC       important for cilia growth (By similarity).
CC       {ECO:0000250|UniProtKB:P31751, ECO:0000303|PubMed:21432781,
CC       ECO:0000303|PubMed:21620960}.
CC   -!- FUNCTION: Several AKT2-specific substrates have been identified,
CC       including ANKRD2, C2CD5, CLK2 and PITX2. May play a role in myoblast
CC       differentiation. In this context, may act through PITX2
CC       phosphorylation. Unphosphorylated PITX2 associates with an ELAVL1/HuR-
CC       containing complex, which stabilizes cyclin mRNA and ensuring cell
CC       proliferation. Phosphorylation by AKT2 impairs this association,
CC       leading to CCND1 mRNA destabilization and progression towards
CC       differentiation (By similarity). Also involved in the negative
CC       regulation of myogenesis in response to stress conditions. In this
CC       context, acts by phosphorylating ANKRD2 (By similarity). May also be a
CC       key regulator of glucose uptake. Regulates insulin-stimulated glucose
CC       transport by the increase of glucose transporter GLUT4 translocation
CC       from intracellular stores to the plasma membrane. In this context, acts
CC       by phosphorylating C2CD5/CDP138 on 'Ser-197' in insulin-stimulated
CC       adipocytes (By similarity). Through the phosphorylation of CLK2 on
CC       'Thr-343', involved in insulin-regulated suppression of hepatic
CC       gluconeogenesis (By similarity). {ECO:0000250|UniProtKB:Q60823}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000250|UniProtKB:P31751};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000250|UniProtKB:P31751};
CC   -!- ACTIVITY REGULATION: Phosphorylation at Thr-309 (in the kinase domain)
CC       and Ser-474 (in the C-terminal regulatory region) is required for full
CC       activation (By similarity). In adipocytes and hepatocytes, the
CC       activation is induced by insulin (PubMed:9512493).
CC       {ECO:0000250|UniProtKB:P31751, ECO:0000269|PubMed:9512493}.
CC   -!- SUBUNIT: Interacts with BTBD10 (By similarity). Interacts with KCTD20
CC       (By similarity). Interacts (via PH domain) with MTCP1, TCL1A and TCL1B;
CC       this interaction may facilitate AKT2 oligomerization and
CC       phosphorylation, hence increasing kinase activity (By similarity).
CC       Interacts with PHB2; this interaction may be important for myogenic
CC       differentiation (By similarity). Interacts (when phosphorylated) with
CC       CLIP3; this interaction promotes cell membrane localization (By
CC       similarity). Interacts with WDFY2 (via WD repeats 1-3) (By similarity).
CC       {ECO:0000250|UniProtKB:P31751, ECO:0000250|UniProtKB:Q60823}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:Q60823}. Nucleus
CC       {ECO:0000250|UniProtKB:Q60823}. Cell membrane {ECO:0000250}; Peripheral
CC       membrane protein {ECO:0000250}. Early endosome
CC       {ECO:0000250|UniProtKB:Q60823}. Note=Through binding of the N-terminal
CC       PH domain to phosphatidylinositol (3,4,5)-trisphosphate
CC       (PtdIns(3,4,5)P3) or phosphatidylinositol (3,4)-bisphosphate
CC       (PtdIns(3,4)P2), recruited to the plasma membrane. Cell membrane
CC       recruitment is facilitated by interaction with CLIP3. Colocalizes with
CC       WDFY2 in early endosomes (By similarity). Localizes within both nucleus
CC       and cytoplasm in proliferative primary myoblasts and mostly within the
CC       nucleus of differentiated primary myoblasts (By similarity).
CC       {ECO:0000250|UniProtKB:P31751, ECO:0000250|UniProtKB:Q60823}.
CC   -!- TISSUE SPECIFICITY: Expressed in adipocytes and hepatocytes (at protein
CC       level). Expressed at low levels in skeletal muscle (at protein level).
CC       {ECO:0000269|PubMed:9512493}.
CC   -!- DOMAIN: Binding of the PH domain to phosphatidylinositol 3,4,5-
CC       trisphosphate (PtdIns(3,4,5)P3) following phosphatidylinositol 3-kinase
CC       alpha (PIK3CA) activation results in AKT2 recruitment to the plasma
CC       membrane, exposition of a pair of serine and threonine residues for
CC       phosphorylation by membrane-associated PDK1 and activatio.
CC       {ECO:0000303|PubMed:21620960}.
CC   -!- PTM: Phosphorylated and activated by PDK1 in the presence of
CC       phosphatidylinositol 3,4,5-trisphosphate (PubMed:9512493).
CC       Phosphorylation on Thr-309 and Ser-474 is required for full activity
CC       (By similarity). {ECO:0000250|UniProtKB:P31751,
CC       ECO:0000269|PubMed:9512493}.
CC   -!- PTM: Ubiquitinated; undergoes both 'Lys-48'- and 'Lys-63'-linked
CC       polyubiquitination. TRAF6-induced 'Lys-63'-linked AKT2 ubiquitination.
CC       When fully phosphorylated and translocated into the nucleus, undergoes
CC       'Lys-48'-polyubiquitination catalyzed by TTC3, leading to its
CC       degradation by the proteasome. {ECO:0000250|UniProtKB:P31751}.
CC   -!- PTM: O-GlcNAcylation at Thr-306 and Thr-313 inhibits activating
CC       phosphorylation at Thr-309 via disrupting the interaction between AKT
CC       and PDK1. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. RAC subfamily. {ECO:0000305}.
CC   -!- CAUTION: In light of strong identity in the primary amino acid
CC       sequence, the 3 AKT kinases were long surmised to play redundant and
CC       overlapping roles. However, it is now known that each AKT may display
CC       specific functions in different cellular events and diseases. AKT1 is
CC       more specifically involved in cellular survival pathways, by inhibiting
CC       apoptotic processes; whereas AKT2 is more specific for the insulin
CC       receptor signaling pathway. Moreover, while AKT1 and AKT2 are often
CC       implicated in many aspects of cellular transformation, the 2 isoforms
CC       act in a complementary opposing manner. The role of AKT3 is less clear,
CC       though it appears to be predominantly expressed in brain.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D30041; BAA06280.1; -; mRNA.
DR   PIR; JC2438; JC2438.
DR   RefSeq; NP_058789.1; NM_017093.1.
DR   AlphaFoldDB; P47197; -.
DR   BMRB; P47197; -.
DR   SMR; P47197; -.
DR   IntAct; P47197; 1.
DR   STRING; 10116.ENSRNOP00000025303; -.
DR   GlyCosmos; P47197; 4 sites, No reported glycans.
DR   GlyGen; P47197; 5 sites, 1 O-linked glycan (1 site).
DR   iPTMnet; P47197; -.
DR   PhosphoSitePlus; P47197; -.
DR   jPOST; P47197; -.
DR   PaxDb; 10116-ENSRNOP00000025303; -.
DR   GeneID; 25233; -.
DR   KEGG; rno:25233; -.
DR   UCSC; RGD:2082; rat.
DR   AGR; RGD:2082; -.
DR   CTD; 208; -.
DR   RGD; 2082; Akt2.
DR   eggNOG; KOG0690; Eukaryota.
DR   InParanoid; P47197; -.
DR   OrthoDB; 3028764at2759; -.
DR   PhylomeDB; P47197; -.
DR   BRENDA; 2.7.11.1; 5301.
DR   Reactome; R-RNO-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-RNO-1358803; Downregulation of ERBB2:ERBB3 signaling.
DR   Reactome; R-RNO-165158; Activation of AKT2.
DR   Reactome; R-RNO-165181; Inhibition of TSC complex formation by PKB.
DR   Reactome; R-RNO-198323; AKT phosphorylates targets in the cytosol.
DR   Reactome; R-RNO-198693; AKT phosphorylates targets in the nucleus.
DR   Reactome; R-RNO-199418; Negative regulation of the PI3K/AKT network.
DR   Reactome; R-RNO-211163; AKT-mediated inactivation of FOXO1A.
DR   Reactome; R-RNO-3769402; Deactivation of the beta-catenin transactivating complex.
DR   Reactome; R-RNO-389357; CD28 dependent PI3K/Akt signaling.
DR   Reactome; R-RNO-389513; CTLA4 inhibitory signaling.
DR   Reactome; R-RNO-392451; G beta:gamma signalling through PI3Kgamma.
DR   Reactome; R-RNO-5218920; VEGFR2 mediated vascular permeability.
DR   Reactome; R-RNO-5628897; TP53 Regulates Metabolic Genes.
DR   Reactome; R-RNO-6804757; Regulation of TP53 Degradation.
DR   Reactome; R-RNO-6804758; Regulation of TP53 Activity through Acetylation.
DR   Reactome; R-RNO-6804759; Regulation of TP53 Activity through Association with Co-factors.
DR   Reactome; R-RNO-69202; Cyclin E associated events during G1/S transition.
DR   Reactome; R-RNO-69656; Cyclin A:Cdk2-associated events at S phase entry.
DR   Reactome; R-RNO-8876198; RAB GEFs exchange GTP for GDP on RABs.
DR   Reactome; R-RNO-8948751; Regulation of PTEN stability and activity.
DR   Reactome; R-RNO-9607240; FLT3 Signaling.
DR   Reactome; R-RNO-9614399; Regulation of localization of FOXO transcription factors.
DR   Reactome; R-RNO-9634638; Estrogen-dependent nuclear events downstream of ESR-membrane signaling.
DR   Reactome; R-RNO-9755511; KEAP1-NFE2L2 pathway.
DR   PRO; PR:P47197; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0005938; C:cell cortex; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005769; C:early endosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0032593; C:insulin-responsive compartment; IDA:RGD.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; ISO:RGD.
DR   GO; GO:0005886; C:plasma membrane; ISO:RGD.
DR   GO; GO:0032587; C:ruffle membrane; ISS:UniProtKB.
DR   GO; GO:0016529; C:sarcoplasmic reticulum; IDA:RGD.
DR   GO; GO:0031982; C:vesicle; IDA:RGD.
DR   GO; GO:0005524; F:ATP binding; IDA:RGD.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0140677; F:molecular function activator activity; ISO:RGD.
DR   GO; GO:0004672; F:protein kinase activity; ISO:RGD.
DR   GO; GO:0005080; F:protein kinase C binding; IPI:RGD.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:RGD.
DR   GO; GO:0071486; P:cellular response to high light intensity; ISO:RGD.
DR   GO; GO:0032870; P:cellular response to hormone stimulus; IEP:RGD.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; IMP:MGI.
DR   GO; GO:0071407; P:cellular response to organic cyclic compound; IDA:RGD.
DR   GO; GO:0006006; P:glucose metabolic process; ISO:RGD.
DR   GO; GO:0005978; P:glycogen biosynthetic process; IEA:UniProtKB-KW.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; ISO:RGD.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:RGD.
DR   GO; GO:0010748; P:negative regulation of long-chain fatty acid import across plasma membrane; ISO:RGD.
DR   GO; GO:0033119; P:negative regulation of RNA splicing; IMP:RGD.
DR   GO; GO:0032287; P:peripheral nervous system myelin maintenance; ISO:RGD.
DR   GO; GO:0043491; P:phosphatidylinositol 3-kinase/protein kinase B signal transduction; IMP:RGD.
DR   GO; GO:0030335; P:positive regulation of cell migration; IMP:RGD.
DR   GO; GO:2000147; P:positive regulation of cell motility; ISO:RGD.
DR   GO; GO:0032000; P:positive regulation of fatty acid beta-oxidation; ISO:RGD.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:RGD.
DR   GO; GO:0046326; P:positive regulation of glucose import; IMP:RGD.
DR   GO; GO:0010907; P:positive regulation of glucose metabolic process; ISO:RGD.
DR   GO; GO:0045725; P:positive regulation of glycogen biosynthetic process; ISO:RGD.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IMP:RGD.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IMP:RGD.
DR   GO; GO:0050927; P:positive regulation of positive chemotaxis; IDA:RGD.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IMP:RGD.
DR   GO; GO:0090314; P:positive regulation of protein targeting to membrane; ISS:UniProtKB.
DR   GO; GO:0009967; P:positive regulation of signal transduction; IMP:RGD.
DR   GO; GO:0010765; P:positive regulation of sodium ion transport; IMP:MGI.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IMP:RGD.
DR   GO; GO:0072659; P:protein localization to plasma membrane; ISO:RGD.
DR   GO; GO:0006417; P:regulation of translation; IEA:UniProtKB-KW.
DR   GO; GO:0001666; P:response to hypoxia; IEP:RGD.
DR   GO; GO:0032868; P:response to insulin; IDA:RGD.
DR   GO; GO:0014850; P:response to muscle activity; IEP:RGD.
DR   GO; GO:0031667; P:response to nutrient levels; IEP:RGD.
DR   GO; GO:0097473; P:retinal rod cell apoptotic process; ISO:RGD.
DR   CDD; cd01241; PH_PKB; 1.
DR   CDD; cd05595; STKc_PKB_beta; 1.
DR   Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1.
DR   Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR034677; Akt2.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR039026; PH_PKB.
DR   InterPro; IPR017892; Pkinase_C.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   PANTHER; PTHR24351:SF192; PROTEIN KINASE C; 1.
DR   PANTHER; PTHR24351; RIBOSOMAL PROTEIN S6 KINASE; 1.
DR   Pfam; PF00169; PH; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00433; Pkinase_C; 1.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF50729; PH domain-like; 1.
DR   SUPFAM; SSF56112; Protein kinase-like (PK-like); 1.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Apoptosis; ATP-binding; Carbohydrate metabolism;
KW   Cell membrane; Cytoplasm; Developmental protein; Disulfide bond; Endosome;
KW   Glucose metabolism; Glycogen biosynthesis; Glycogen metabolism;
KW   Glycoprotein; Kinase; Manganese; Membrane; Metal-binding;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Sugar transport; Transferase;
KW   Translation regulation; Transport; Ubl conjugation.
FT   CHAIN           1..481
FT                   /note="RAC-beta serine/threonine-protein kinase"
FT                   /id="PRO_0000085610"
FT   DOMAIN          5..108
FT                   /note="PH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00145"
FT   DOMAIN          152..409
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          410..481
FT                   /note="AGC-kinase C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00618"
FT   ACT_SITE        275
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         158..166
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         181
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         280
FT                   /ligand="Mn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29035"
FT                   /evidence="ECO:0000250|UniProtKB:P31751"
FT   BINDING         293
FT                   /ligand="Mn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29035"
FT                   /evidence="ECO:0000250|UniProtKB:P31751"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0000250|UniProtKB:P31751"
FT   MOD_RES         34
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P31751"
FT   MOD_RES         126
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P31751"
FT   MOD_RES         309
FT                   /note="Phosphothreonine; by PDPK1"
FT                   /evidence="ECO:0000250|UniProtKB:P31751"
FT   MOD_RES         447
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P31751"
FT   MOD_RES         451
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         461
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         474
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P31751"
FT   MOD_RES         478
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P31751"
FT   CARBOHYD        128
FT                   /note="O-linked (GlcNAc) serine"
FT                   /evidence="ECO:0000250"
FT   CARBOHYD        131
FT                   /note="O-linked (GlcNAc) serine"
FT                   /evidence="ECO:0000250"
FT   CARBOHYD        306
FT                   /note="O-linked (GlcNAc) threonine"
FT                   /evidence="ECO:0000250"
FT   CARBOHYD        313
FT                   /note="O-linked (GlcNAc) threonine"
FT                   /evidence="ECO:0000250"
FT   DISULFID        60..77
FT                   /evidence="ECO:0000250"
SQ   SEQUENCE   481 AA;  55543 MW;  3C4BE65B2F376F85 CRC64;
     MNEVSVIKEG WLHKRGEYIK TWRPRYFLLK SDGSFIGYKE RPEAPDQTLP PLNNFSVAEC
     QLMKTERPRP NTFVIRCLQW TTVIERTFHV DSPDEREEWI RAIQMVANSL KQRGPGEDAM
     DYKCGSPSDS STSEMMEVAV SKARAKVTMN DFDYLKLLGK GTFGKVILVR EKATGRYYAM
     KILRKEVIIA KDEVAHTVTE SRVLQNTRHP FLTALKYAFQ THDRLCFVME YANGGDLFFH
     LSRERVFTED RARFYGAEIV SALEYLHSTD VVYRDIKLEN LMLDKDGHIK ITDFGLSKEG
     ISDGATMKTF CGTPEYLAPE VLEDNDYGRA VDWWGLGVVM YEMMCGRLPF YNQDHERLFE
     LILMEEIRFP RTLGPEAKSL LAGLLKKDPK QRLGGGPSDA KEVMEHRFFL SINWQDVVQK
     KLLPPFKPQV TSEVDTRYFD DEFTAQSITI TPPDRYDSLG SLELDQRTHF PQFSYSASIR
     E
//
